• Lung Cancer Group Cologne
  • Contact
  • Privacy Policy
  • English
    • Deutsch (German)
Netzwerk Genomische Medizin Lungenkrebs
  • Doctors
    • Information
      • Service invoicing
      • Service invoicing for pathologists
    • Clinical trials
      • Lung Cancer Study Group
      • General information
  • Patients
    • General information
      • Driver mutations in lung cancer
      • New immunotherapeutic therapeutic approaches
      • Second Opinion service
      • Molecular Diagnostics
      • New therapeutic approaches from genomic research
    • Clinical trials
      • Lung Cancer Study Group
      • General information
      • What is a clinical trial?
      • Participation in a trial
    • Find doctors nearby
  • The Network
    • Aims
    • Funding
    • Our team
    • Related links
  • Driver mutations
  • Diagnostics
  • Hybrid-capture
  • Fast-track analysis for first-line treatment
Select Page

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W

Journal: Cancer Research
Published: July 2011

  • © 2016-2018 Network Genomic Medicine (NGM)
  • Contact
  • Imprint
  • Privacy Policy

Designed by Elegant Themes | Powered by WordPress